Fludarabine/busulfan conditioning based allogeneic hematopoietic cell transplantation for myelofibrosis: Role of ruxolitinib in improving survival outcomes

Primary myelofibrosis (MF) is a Philadelphia-negative myeloproliferative neoplasm characterized by clonal myeloid proliferation, splenomegaly, bone marrow fibrosis, and heterogenous symptom burden [1-3]. Non-transplant treatment options have traditionally included cytoreductive therapies (hydroxyurea, busulfan, interferon- α), immunomodulatory drugs, androgens, splenic irradiation and splenectomy – though these are primarily palliative [4]. In the last decade, major advances in the understanding of the molecular basis of MF have been achieved, importantly the pivotal role of the JAK-STAT pathway.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research

Related Links:

Myelofibrosis (MF) is a BCR-ABL1 negative myeloproliferative neoplasm (MPN) that arises from hematopoietic stem/progenitor cells frequently harboring a somatic driver mutation in one of three genes: JAK2, CALR or MPL. Pathologic features of this hematologic malignancy include myeloproliferation, diffuse bone marrow fibrosis, and overactivation of the JAK-STAT pathway resulting in enhanced inflammatory cytokine release. Common clinical manifestations of MF include systemic symptoms, abnormal peripheral blood counts and splenomegaly, however, it has become increasingly appreciated that there is significant clinical heterogen...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Leukemia, Published online: 25 February 2020; doi:10.1038/s41375-020-0778-0A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
Source: Leukemia - Category: Hematology Authors: Source Type: research
Conditions:   Accelerated/Blast-phase Myeloproliferative Neoplasm;   Chronic-phase Myelofibrosis;   IDH2 Mutation Interventions:   Drug: Ruxolitinib;   Drug: Enasidenib Sponsors:   Michal Bar-Natan;   Celgene Corporation;   Incyte Corporation;   Myeloproliferative Neoplasms Research Consortium;   National Institutes of Health (NIH);   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Essential Thrombocythemia;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Primary Myelofibrosis;   Secondary Myelofibrosis Interventions:   Drug: Decitabine;   Drug: Ruxolitinib;   Drug: Fedratinib Sponsors:   University of Washington;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Accelerated/Blast-phase Myeloproliferative Neoplasm;   Chronic-phase Myelofibrosis;   IDH2 Mutation Interventions:   Drug: Ruxolitinib;   Drug: Enasidenib Sponsors:   Michal Bar-Natan;   Celgene Corporation;   Incyte Corporation;   Myeloproliferative Neoplasms Research Consortium;   National Institutes of Health (NIH);   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Essential Thrombocythemia;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Primary Myelofibrosis;   Secondary Myelofibrosis Interventions:   Drug: Decitabine;   Drug: Ruxolitinib;   Drug: Fedratinib Sponsors:   University of Washington;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Accelerated/Blast-phase Myeloproliferative Neoplasm;   Chronic-phase Myelofibrosis;   IDH2 Mutation Interventions:   Drug: Ruxolitinib;   Drug: Enasidenib Sponsors:   Michal Bar-Natan;   Celgene Corporation;   Incyte Corporation;   Myeloproliferative Neoplasms Research Consortium;   National Institutes of Health (NIH);   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Leukemia, Published online: 24 February 2020; doi:10.1038/s41375-020-0769-1Chromosome 21 gain is dispensable for transient myeloproliferative disorder driven by a novel GATA1 mutation
Source: Leukemia - Category: Hematology Authors: Source Type: research
ConclusionsSelective JAK2 inhibition reduces atherogenesis by suppressing excessive myelopoiesis in hypercholesterolemicApoe−/− mice. These findings suggest selective JAK2 inhibition as a potential therapeutic approach to decrease ACD risk in patients with increased myelopoiesis and leukocytosis.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
To explore the clinical features of the patients with BCR-ABL1-negative chronic myeloproliferative neoplasms (MPNs) in our hospital and to reveal the unique features of BCR-ABL1-negative MPNs patients in our cent...
Source: Molecular Cytogenetics - Category: Molecular Biology Authors: Tags: Research Source Type: research
More News: Biology | Hematology | Molecular Biology | Myeloproliferative Disorders | Palliative | Splenectomy | Transplants